KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CareDx (CDNA) Shares Outstanding (Weighted Average) (2016 - 2025)

CareDx (CDNA) has disclosed Shares Outstanding (Weighted Average) for 13 consecutive years, with $53.3 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 0.97% to $53.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $53.3 million through Dec 2025, up 0.97% year-over-year, with the annual reading at $53.3 million for FY2025, 0.97% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $53.3 million in Q4 2025 for CareDx, up from $52.5 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $55.3 million in Q1 2025 to a low of $51.2 million in Q1 2021.
  • Historically, Shares Outstanding (Weighted Average) has averaged $53.0 million across 5 years, with a median of $53.1 million in 2022.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): increased 19.52% in 2021 and later fell 3.64% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $52.2 million in 2021, then rose by 2.07% to $53.3 million in 2022, then grew by 0.83% to $53.8 million in 2023, then fell by 1.84% to $52.8 million in 2024, then rose by 0.97% to $53.3 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for CDNA at $53.3 million in Q4 2025, $52.5 million in Q3 2025, and $54.8 million in Q2 2025.